<DOC>
	<DOC>NCT01475370</DOC>
	<brief_summary>The purpose of this study is to assess the safety of OCV-501 in patients with AML who completed the Study 311-10-001 and were judged that there was no relapse by any inspections in the end of the study.</brief_summary>
	<brief_title>Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Patients who completed the Study 31110001 and were judged that there was no relapse by any inspections in the end of the study. Patients who are capable of giving informed consent Patients failed to discontinue the Study 31110001 even though patients met the discontinuation criteria. Patients who have participated in any other clinical trials , excluding the Study 31110001).</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>WT1</keyword>
</DOC>